Neogen Chemicals Q4 Review - Next Growth Phase To Emanate From Pharma Venture: ICICI Direct
An employee mixes a chemical solution at the research laboratory. (Photographer: Dario Pignatelli/Bloomberg)

Neogen Chemicals Q4 Review - Next Growth Phase To Emanate From Pharma Venture: ICICI Direct


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Neogen Chemicals Ltd. reported topline growth of 13% YoY to Rs 92.7 crore against our expectation of Rs 87.1 crore.

The growth was driven by higher growth in the inorganic chemical segment (up 31% YoY) largely on account of better volume growth.

Revenue from organic chemical was up 7% YoY to Rs 72 crore.

Growth from organic chemical segment remained subdued owing to capacity constraint.

Operating profit margin for the quarter expanded 80 basis points YoY to 20% leading to Ebitda growth of 17% YoY to Rs 18.5 crore versus our estimate of Rs 17.2 crore.

Click on the attachment to read the full report:

ICICI Direct Neogen Chemicals Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.